Trials / Completed
CompletedNCT01483014
Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, tolerability of imatinib in the neoadjuvant treatment (pre-operatory) of patients with GIST. It will also evaluate the potential of imatinib to convert a tumor from inoperable to operable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | imatinib mesylate |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2011-12-01
- Last updated
- 2016-11-18
Locations
11 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01483014. Inclusion in this directory is not an endorsement.